Skip to content

Evaluating safety and efficacy of Kangbingdu Koufuye in the treatment of adults' influenza and common cold: multicentre, randomized, double blind, parallel placebo-controlled trial

Evaluating safety and efficacy of Kangbingdu Koufuye in the treatment of adults' influenza and common cold: multicentre, randomized, double blind, parallel placebo-controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002399
Enrollment
Unknown
Registered
2012-08-09
Start date
2012-08-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza and common cold

Interventions

Kangbingdu Koufuye Group:Kangbingdu Koufuye
Control:Placebo

Sponsors

China Academy of Chinese Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years old and elder than 18 years; 2. To be diagnosed with influenza and common cold; 3. The symptoms appeared within 48 hours; 4. The patient has signed the informed consent; 5. Did not use medication of treating cold in past 72 hours regularly until enrollment; 6. WBC count 12*10^9/L and more.

Exclusion criteria

Exclusion criteria: 1. Cold with pneumonia, bronchitis, tympanitis, isthmitis, vital myocarditis, acute nephritis, rheumatic arthritis; 2. Liver and kidney dysfunction; 3. Allergic constitution, a clear history of allergy to components: Banlanggen, Shigao, Lugen, Dihuang, Yujin, Zhimu, Shichangpu, Guanghuoxiang, Lianqiao; 4. Pregnancy or lactation period; 5. Suspect of severe influenza or other severe disease; 6. Inefficient of spleen and stomach with diarrhoea symptom; 7. Intelligence and behavior disorders; 8. To be involved in another clinical trial of cold drugs during past one month; 9. The patient who will unable to complete the study, such as will moving soon.

Design outcomes

Primary

MeasureTime frame
Rate of improvement of the symptoms;time of fever clearance;The time of remission of the fever;Recovery rate;

Secondary

MeasureTime frame
vital signs;WBC and liver function as well as kidney function;ECG;

Countries

China

Contacts

Public ContactHE Li-Yun

China Academy of Chinese Medical Science

hely3699@163.com+86 010 64014411-2408

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026